Silence Therapeutics is "committed to defending its intellectual property".
Showing 25 of 1882
The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) for the treatment of certain lung cancer patients.
“Overall, the board is encouraged by the growing momentum in the business and the outlook for genedrive"
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
Sachem Head Capital Management reportedly wants Shire to offload or spin-off some of its assets as it grows frustrated with the falling share price
CS analysts say AstraZeneca is finally starting to get over the patent expiries of several blockbuster drugs, including Crestor, Seroquel and Nexium
Costs associated with supply issues during the third quarter are expected to hit margins
genedrive and Sysmex Europe believe there is a major opportunity to support tackling the global burden of the hepatitis C disease
Huanzhong Biotech and Wanma Technology have both signed 3-year exclusive distribution agreements
ShoreCap cut its price target to 4,600p from 5,154p on AstraZeneca and left its rating at ‘hold’.
“This agreement highlights how rapidly we can grow and we are committed to securing similar commercial partnerships as we transform the value fundamentals of our company," said WideCells chief executive, João Andrade
“We continue to believe that several third party late-stage RNAi candidates require licences under our chemical modification patent portfolio,” said Silence chief executive Ali Mortazavi
It is unclear how much of a stake in Smith & Nephew that Elliott owns or what its plans are for the company, Bloomberg reported
The poster, "Preservation of Gut Microbiome Following Ridinilazole versus Fidaxomicin Treatment of Clostridium difficile Infection," is available for download on Summit's web site
"The Breakthrough Therapy Designation acknowledges not only Tagrisso's potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease”
“This work has the potential to uncover a whole new area in cancer therapeutics"
The FTSE 100-listed company said it has started to search for a new chief executive to replace Olivier Bohuon
The urgency and size of the market offers huge potential for any company that can come up with a new way to treat infections safely
Avacta chief executive, Dr Alastair Smith, said the collaboration could lead to “multiple therapeutic benefits and create a best-in-class gene therapy combination with significant potential”
Shares are being issued at 800p each, which is a modest 2% discount to Wednesday’s closing price
The shares rose on the news, despite the company intending to issue shares at a slight discount
The SkinBiotix platform has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration
The REVIVE-2 Phase III trial pitted Motif’s iclaprim treatment against vancomycin in patients with acute bacterial skin and skin structure infections
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
The better-than-expected outcome reflects a trebling in the share price of Immupharma